5.65
+0.04(+0.71%)
Currency In USD
Address
2400 District Avenue
Burlington, MA 01803
United States of America
Phone
617 517 0730
Sector
Healthcare
Industry
Biotechnology
Employees
162
First IPO Date
November 17, 2017
| Name | Title | Pay | Year Born |
| Mr. John H. Tucker | President, Chief Executive Officer, Principal Executive Officer & Director | 1.05M | 1963 |
| Ms. Rachael Nokes | Chief Financial Officer | 632,154 | 1976 |
| Mr. Steve C. Parsons | Senior Vice President of Commercial | 0 | N/A |
| Dr. John Mohr Pharm.D. | Senior Vice President of Clinical Development & Medical Affairs | 0 | N/A |
| Ms. Katherine Taudvin | Vice President of Corporate Affairs & Human Resources | 0 | N/A |
| Mr. Michael D. Hassman | Senior Vice President of Technical Operations | 0 | N/A |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.